Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) has announced its participation in the Lytham Partners Fall 2024 Investor Conference, scheduled for October 1, 2024. The virtual event will feature a webcasted presentation by Lisa Conte, the company's founder, president, and CEO, at 1:15pm Eastern. Investors can access the webcast through a provided link, with a replay available after the event.

In addition to the presentation, Jaguar Health's management team will be available for one-on-one virtual meetings with investors throughout the conference. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event through the provided link.

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, will exhibit Gelclair, an FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting from September 29 to October 2, 2024, in Washington, DC. Jaguar plans to launch Gelclair commercially in the U.S. in October 2024.

Gelclair is a protective gel that manages pain by adhering to the mouth's mucosal surface, providing relief for oral lesions, including those caused by oral mucositis/stomatitis. Unlike other products, it doesn't numb or sting the mouth. Oral mucositis, also known as "chemo mouth," affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients treated with chemotherapy and radiotherapy. It can lead to hospitalization, treatment delays, and increased management costs.

The economic impact is significant, with a study showing that severe mucositis/pharyngitis in head and neck cancer patients can result in incremental costs exceeding $17,244 per patient. Jaguar aims to raise awareness among oncologists about Gelclair and its expanding focus on cancer supportive care at the ASTRO Annual Meeting.

Jaguar Health (NASDAQ:JAGX) has announced that its founder, president, and CEO, Lisa Conte, will present at the MedInvest Biotech & Pharma Investor Conference on September 19, 2024, in New York City. The presentation is scheduled for 9:55 AM to 10:10 AM Eastern time. Conte will also participate in one-on-one meetings during the event, which runs from September 18-19.

This conference provides Jaguar Health with an opportunity to showcase its developments and connect with potential investors in the biotech and pharmaceutical sectors. Interested parties can register for the presentation through a provided link, allowing them to gain insights into Jaguar Health's current projects and future prospects.

Jaguar Health (NASDAQ:JAGX) has appointed Susan Krizancic as National Sales Director for its family company Napo Pharmaceuticals. Krizancic, a biopharmaceutical industry veteran with 30 years of experience, will lead sales for Jaguar's commercialized oncology and HIV products. This includes the planned October 2024 launch of Gelclair, an FDA-approved oral mucositis prescription product for cancer supportive care.

Krizancic's appointment is expected to bolster Jaguar's commercial strategy, particularly in cancer and GI supportive care. The company will also continue to focus on sales of crofelemer (Mytesi), its FDA-approved drug for noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Jaguar's CEO, Lisa Conte, expressed confidence in Krizancic's ability to drive sales and execute the company's in-licensing growth strategy.

Jaguar Health (NASDAQ:JAGX) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The company's founder, president, and CEO, Lisa Conte, will deliver a virtual presentation and meet with investors during the event.

The conference will be held both virtually and in-person at the Lotte New York Palace. Jaguar Health's on-demand virtual presentation will be available starting at 7:00 AM Eastern on Monday, September 9, 2024. Interested parties can access the presentation through a provided webcast link and register for the conference online.

This event presents an opportunity for Jaguar Health to showcase its developments and engage with potential investors, potentially impacting its stock performance and market visibility.

Jaguar Health (NASDAQ:JAGX) is celebrating National Service Dog Month, highlighting its commitment to supportive cancer care for both humans and dogs. The company's FDA conditionally approved drug, Canalevia-CA1, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, is available by prescription from veterinarians and on Chewy. Jaguar's ongoing 'Make Cancer Less Shitty' campaign emphasizes the challenges of cancer treatments, especially for metastatic patients. The campaign features patient ambassadors sharing their experiences on the website makecancerlessshitty.com and on X under the handle cancersuckless.

Jaguar's CEO, Lisa Conte, stressed the alignment between service dogs' role in improving quality of life and Jaguar's mission to provide supportive care for complex diseases like cancer in both people and dogs.

Jaguar Health (NASDAQ:JAGX) has announced key near-term milestones in a new Innovators with Jane King interview with CEO Lisa Conte. The company is focusing on two main activities:

1. Planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® in the U.S.

2. Progressing rare disease development with multiple investigator-initiated proof-of-concept studies for crofelemer in microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Results are expected by the end of 2024 and throughout 2025.

Jaguar also plans to enroll first patients for two global phase 2 studies for MVID and SBS-IF in Q4 2024. The company is continuing analysis of its pivotal phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, with a focus on breast and lung cancer patients.

Jaguar Health (NASDAQ:JAGX) announced that Jordan's Industrial Property Protection Directorate has issued a new patent to Napo Pharmaceuticals for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication of SBS.

Jaguar is supporting independent investigator-initiated proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease (MVID) across the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.

Napo currently holds approximately 173 patents and 60 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.

Jaguar Health (NASDAQ:JAGX) announced that Dr. Eduardo Zimmer, a key collaborator with their joint venture Magdalena Biosciences, has received the prestigious Blas Frangione Early Career Achievement Award for 2024. This award recognizes early career researchers in Alzheimer's and dementia research. Magdalena, approximately 40% owned by Jaguar, is focused on developing novel, natural prescription psychoactive medicines from plants for mental health indications.

Magdalena recently initiated preclinical studies in Brazil to evaluate two botanical drug candidates for treating depression, anxiety, ADHD, and other neuropsychiatric conditions in adults. These studies use FDG PET scans to assess differential neuronal activity, with analysis performed by Dr. Zimmer's consultancy. The research aims to determine optimal dosing and therapeutic indications for potential future FDA approval as botanical drugs.